INDIA- Molbio Diagnostics has launched a novel test for the differential diagnosis of HIV 1 and HIV 2 with viral loads within 60 minutes.

The company has claimed that the test works on the existing Truelab infrastructure and will require no additional set-ups and equipment. 

Sriram Natarajan, CEO, Founder, and Director of Molbio Diagnostics stated that HIV remains a serious public health issue that affects both people and economies.

He emphasized early detection and testing was key to halt the spread of HIV adding that the (World Health Organization) WHO has mandated that only viral load testing will be used to monitor patients receiving treatment.

“HIV was first identified more than 50 years ago, and we don’t have a cure yet. So testing is the first step to preventing the further spread of the disease,” Said  Sriram.

HIV weakens the immune system, making the infected individual more vulnerable to other illnesses and infections. HIV-1 is the more prevalent of the two kinds of HIV, whereas HIV-2 is less frequent and contagious.

Truenat has now achieved its goal of being a multi-disease diagnostics platform. Currently, the platform is running more than 30 validated and regulatory-approved assays.

Truenat HIV 1/ HIV 2 will give everyone access to early detection and estimation of the viral load because it is a point of care platform.

The test is a portable, battery-powered, IoT-enabled, Real-Time PCR platform with a sample-to-result time of less than 1 hour, according to the diagnostic company.

Truenat has now achieved its goal of being a multi-disease diagnostics platform. Currently, the platform is running more than 30 validated and regulatory-approved assays.

In addition to Tuberculosis, a wide range of bacterial pathogens, drug resistance, Covid19, the entire range of Hepatitis tests, multiple other tests for viral diseases, and Scrub Typhus are currently being run on the Truenat platform.

Vector-borne diseases such as Dengue, Chikungunya, and Malaria can also be detected by the platform in both public and private healthcare settings across the country.

Truenat has also been thoroughly validated by The Indian Council of Medical Research (ICMR) and WHO approvals for sensitive and quick detection of Multidrug-resistant TB (MDR TB).

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE